Citations

1. Gerard J. The Herbal. Revised and Enlarged. In: Johnson T, ed. 1975 ed. New York: Dover Publications; 1633.
2. St. John's wort. In: Blumenthal M, Busse W, Goldberg A et al. The Complete German Commission E Monographs. Austin, Texas: American Botanical Council: Integrative Medicine Communications; 1998:214-215.
3. Upton R. St. John's wort. American Herbal Pharmacopoeia. Scotts Valley, Calif; 1997.
4. ESCOP. Hyperici herba. ESCOP Monographs: the Scientific Foundation for Herbal Medicinal Products. 2nd ed. Exeter, UK: European Scientific Cooperative on Phytotherapy and Thieme; 2003:257-281.
5. McKenna D, Jones K, Hughes K, Humphrey S. St John's wort. Botanical Medicines. 2nd ed. Binghamton, NY: Haworth Press; 2002:923-986.
6. Weiss R. Herbal Medicine. Meuss A, Translator. 6th ed. Beaconsfield, UK: Beaconsfield Publishers Ltd; 1988.
7. Johne A, Brockmoller J, Bauer S et al. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin Pharmacol Ther 1999;66:338-345.
8. Ruschitzka F, Meier PJ, Turina M et al. Acute heart transplant rejection due to Saint John's wort [letter]. Lancet 2000;355:548-549.
9. Piscitelli SC, Burstein AH, Chaitt D et al. Indinavir concentrations and St John's wort [letter]. Lancet 2000;355:547-548.
10. Ernst E. Second thoughts about safety of St John's wort. Lancet 1999;354:2014-2016.
11. Fugh-Berman A, Ernst E. Herb-drug interactions: review and assessment of report reliability. Br J Clin Pharmacol 2001;52:587-595.
12. Meyer JR, Generali JA, Karpinski JL. Evaluation of herbal-drug interaction data in tertiary resources. Hosp Pharm 2004;39:149-160.
13. Izzo AA. Drug interactions with St. John's wort (Hypericum perforatum): a review of the clinical evidence. Int J Clin Pharmacol Ther 2004;42:139-148.
14. Mills E, Montori VM, Wu P et al. Interaction of St John's wort with conventional drugs: systematic review of clinical trials. BMJ 2004;329:27-30.
15. US Food and Drug Administration (FDA). Guidelines for industry: in vivo drug metabolism/drug interaction studies—study design, data analysis and recommendations for dosing and labeling. 1999 vol: www.fda.gov/cber/gdlns/metabol.pdf; 7/4/04.
16. Committee on Safety of Medicines (CSM). Message from Professor A Breckenridge, Chairman, CSM (UK); February 2000.
17. Irish Medical Board (IMB). Herbal Medicines Project: final report; 2001. http://www.euroherb.com/.
18. Lumpkin M, Alpert S. Risk of drug interactions with St. John's Wort and indinavir and other drugs. FDA Public Health Advisory. CDER; 2000. http://www.fda.gov/cder/drug/advisory/stjwort.htm.
19. Obach RS. Inhibition of human cytochrome P450 enzymes by constituents of St. John's wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther 2000;294:88-95.
20. Budzinski JW, Foster BC, Vandenhoek S, Arnason JT. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 2000;7:273-282.
21. Roby CA, Anderson GD, Kantor E et al. St John's wort: effect on CYP3A4 activity. Clin Pharmacol Ther 2000;67:451-457.
22. Gurley BJ, Gardner SF, Hubbard MA et al. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther 2002;72:276-287.
23. Wang L-S, Zhou G, Zhu B et al. St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. Clin Pharmacol Ther 2004;75:191-197.
24. Markowitz JS, DeVane CL, Boulton DW et al. Effect of St. John's wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers. Life Sci 2000;66:L133-L139.
25. Gerwertz N, Ereshefsky B, Lam Y et al. Determination of SJW differential metabolism at CYP2D6 and CYP3A4 using dextromethorphan probe technology. Abstracts from the 39th Annual Meeting, New Clinical Drug Evaluation Unit. Boca Raton, Fla; 1999:130.
26. Wang Z, Gorski JC, Hamman MA et al. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 2001;70:317-326.
27. Dresser GK, Schwarz UI, Wilkinson GR, Kim RB. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. Clin Pharmacol Ther 2003;73:41-50.
28. Durr D, Stieger B, Kullak-Ublick GA et al. St John's wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 2000;68:598-604.
29. Wenk M, Todesco L, Krahenbuhl S. Effect of St John's wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xanthine oxidase in healthy males and females. Br J Clin Pharmacol 2004;57:495-499.
30. Wang EJ, Barecki-Roach M, Johnson WW. Quantitative characterization of direct P-glycoprotein inhibition by St John's wort constituents hypericin and hyperforin. J Pharm Pharmacol 2004;56:123-128.

31. Markowitz JS, Donovan JL, DeVane CL et al. Effect of St. John's wort on drug metabolism by induction of cytochrome p450 3A4 enzyme. Obstet Gynecol Surv 2004;59:358-359.
32. Komoroski BJ, Zhang S, Cai H et al. Induction and inhibition of cytochromes p450 by the St. John's wort constituent hyperforin in human hepatocyte cultures. Drug Metab Dispos 2004;32:512-518.
33. Chen Y, Ferguson SS, Negishi M, Goldstein JA. Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor. J Pharmacol Exp Ther 2004;308:495-501.
34. Madabushi R, Frank B, Drewelow B et al. Hyperforin in St. John's wort drug interactions. Eur J Clin Pharmacol 2006:1-9.
35. Bailey DG, Dresser GK, Bend JR. Bergamottin, lime juice, and red wine as inhibitors of cytochrome P450 3A4 activity: comparison with grapefruit juice. Clin Pharmacol Ther 2003;73:529-537.
36. Huang SM, Hall SD, Watkins P et al. Drug interactions with herbal products and grapefruit juice: a conference report. Clin Pharmacol Ther 2004;75:1-12.
37. Rengelshausen J, Banfield M, Riedel KD et al. Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics. Clin Pharmacol Ther 2005;78:25-33.
38. Xie HG, Kim RB. St John's wort-associated drug interactions: short-term inhibition and long-term induction? Clin Pharmacol Ther 2005;78:19-24.
39. Moore LB, Goodwin B, Jones SA et al. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci U S A 2000;97:7500-7502.
40. Watkins RE, Maglich JM, Moore LB et al. 2.1 A crystal structure of human PXR in complex with the St. John's wort compound hyperforin. Biochemistry 2003;42:1430-1438.
41. Jones SA, Moore LB, Shenk JL et al. The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. Mol Endocrinol 2000;14:27-39.
42. Kliewer SA. The nuclear pregnane X receptor regulates xenobiotic detoxification. J Nutr 2003;133:2444S-2447S.
43. Waxman DJ. P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR. Arch Biochem Biophys 1999;369:11-23.
44. Schwarz D, Kisselev P, Roots I. St. John's wort extracts and some of their constituents potently inhibit ultimate carcinogen formation from benzo[a]pyrene-7,8-dihydrodiol by human CYP1A1. Cancer Res 2003;63:8062-8068.
45. Brockmoller J, Kirchheiner J, Meisel C, Roots I. Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment. Pharmacogenomics 2000;1:125-151.
46. Dorne JLCM, Walton K, Renwick AG. Human variability for metabolic pathways with limited data (CYP2A6, CYP2C9, CYP2E1, ADH, esterases, glycine and sulphate conjugation). Food Chem Toxicol 2004;42:397-421.
47. Foster BC, Vandenhoek S, Hana J et al. In vitro inhibition of human cytochrome P450–mediated metabolism of marker substrates by natural products. Phytomedicine 2003;10:334-342.
48. Henderson L, Yue QY, Bergquist C et al. St John's wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol 2002;54:349-356.
49. Hennessy M, Kelleher D, Spiers JP et al. St John's wort increases expression of P-glycoprotein: implications for drug interactions. Br J Clin Pharmacol 2002;53:75-82.
50. Dresser GK, McDonald W, Kim RB, Bailey DG. Evaluation of herbal products as potential inhibitors of MDR1. Clin Pharmacol Ther 2004;75:P79.
51. Zhou S, Lim LY, Chowbay B. Herbal modulation of P-glycoprotein. Drug Metab Rev 2004;36:57-104.
52. Traber MG. Vitamin E, nuclear receptors and xenobiotic metabolism. Arch Biochem Biophys 2004;423:6-11.
53. Maglich JM, Stoltz CM, Goodwin B et al. Nuclear pregnane X receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Mol Pharmacol 2002;62:638-646.
54. Moore LB, Maglich JM, McKee DD et al. Pregnane X receptor (PXR), constitutive androstane receptor (CAR), and benzoate X receptor (BXR) define three pharmacologically distinct classes of nuclear receptors. Mol Endocrinol 2002;16:977-986.
55. Moore JT, Kliewer SA. Use of the nuclear receptor PXR to predict drug interactions. Toxicology 2000;153:1-10.
56. Moore LB, Parks DJ, Jones SA et al. Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. J Biol Chem 2000;275:15122-15127.
57. Forman BM. Polymorphisms in promiscuous PXR: an explanation for interindividual differences in drug clearance? Pharmacogenetics 2001;11:551-552.
58. Lamba J, Lamba V, Schuetz E. Genetic variants of PXR (NR1I2) and CAR (NR1I3) and their implications in drug metabolism and pharmacogenetics. Curr Drug Metab 2005;6:369-383.

59. Pascussi JM, Gerbal-Chaloin S, Drocourt L et al. The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors. Biochim Biophys Acta 2003;1619:243-253.
60. Treasure JE. Warding off evil in the 21st century: St. John's wort as a xenosensory activator? J Am Herbalists Guild 2005;6:48-51.
61. Janosek J, Hilscherova K, Blaha L, Holoubek I. Environmental xenobiotics and nuclear receptors: interactions, effects and in vitro assessment. Toxicol In Vitro 2006;20:18-37.
62. Pal D, Mitra AK. MDR- and CYP3A4-mediated drug-herbal interactions. Life Sci 2006;78:2131-2145.
63. Ernst E. St John's wort supplements endanger the success of organ transplantation. Arch Surg 2002;137:316-319.
64. Dresser GK, Schwarz UI, Wilkinson GR, Kim RB. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. Clin Pharmacol Ther 2003;73:41-50.
65. Lin JH. Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. Adv Drug Deliv Rev 2003;55:53-81.
66. Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 2003;42:59-98.
67. Di Marco MP, Edwards DJ, Wainer IW, Ducharme MP. The effect of grapefruit juice and seville orange juice on the pharmacokinetics of dextromethorphan: the role of gut CYP3A and P-glycoprotein. Life Sci 2002;71:1149-1160.
68. Bhardwaj RK, Glaeser H, Becquemont L et al. Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 2002;302:645-650.
69. Benet LZ, Cummins CL. The drug efflux-metabolism alliance: biochemical aspects. Adv Drug Deliv Rev 2001;50 Suppl 1:S3-S11.
70. Cummins CL, Jacobsen W, Benet LZ. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 2002;300:1036-1045.
71. Cummins CL, Wu CY, Benet LZ. Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. Clin Pharmacol Ther 2002;72:474-489.
72. Backman JT, Olkkola KT, Neuvonen PJ. Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther 1996;59:7-13.
73. Tsunoda SM, Harris RZ, Christians U et al. Red wine decreases cyclosporine bioavailability. Clin Pharmacol Ther 2001;70:462-467.
74. Burstein AH, Horton RL, Dunn T et al. Lack of effect of St John's wort on carbamazepine pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 2000;68:605-612.
75. Armstrong SC, Cozza KL, Sandson NB. Six patterns of drug-drug interactions. Psychosomatics 2003;44:255-258.
76. Xie R, Tan LH, Polasek EC et al. CYP3A and P-glycoprotein activity induction with St. John's wort in healthy volunteers from 6 ethnic populations. J Clin Pharmacol 2005;45:352-356.
77. Gurley BJ, Gardner SF, Hubbard MA et al. Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John's wort, garlic oil, Panax ginseng and Ginkgo biloba. Drugs Aging 2005;22:525-539.
78. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs 2001;61:2163-2175.
79. Butterweck V, Derendorf H, Gaus W et al. Pharmacokinetic herb-drug interactions: are preventive screenings necessary and appropriate? Planta Med 2004;70:784-791.
80. Williamson EM. Interactions between herbal and conventional medicines. Expert Opin Drug Saf 2005;4:355-378.
81. Treasure JE. MEDLINE and the mainstream manufacture of misinformation. J Am Herbalists Guild 2006;6:50-56.
82. Singh YN. Potential for interaction of kava and St. John's wort with drugs. J Ethnopharmacol 2005;100:108-113.
83. Arold G, Donath F, Maurer A et al. No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St John's wort extract. Planta Med 2005;71:331-337.
84. Medina MA, Martinez-Poveda B, Amores-Sanchez MI, Quesada AR. Hyperforin: more than an antidepressant bioactive compound? Life Sci 2006;79:105-111.
85. Walter G, Rey JM, Harding A. Psychiatrists' experience and views regarding St John's wort and "alternative" treatments. Aust N Z J Psychiatry 2000;34:992-996.
86. Schulz V. Incidence and clinical relevance of the interactions and side effects of Hypericum preparations. Phytomedicine 2001;8:152-160.
87. Di Carlo G, Borrelli F, Izzo AA, Ernst E. St John's wort: Prozac from the plant kingdom. Trends Pharmacol Sci 2001;22:292-297.
88. Bladt S, Wagner H. Inhibition of MAO by fractions and constituents of Hypericum extract. J Geriatr Psychiatry Neurol 1994;7 Suppl 1:S57-59.
89. Cott JM. In vitro receptor binding and enzyme inhibition by Hypericum perforatum extract. Pharmacopsychiatry 1997;30 Suppl 2:108-112.
90. Singer A, Wonnemann M, Muller WE. Hyperforin, a major antidepressant constituent of St. John's wort, inhibits serotonin uptake by elevating free intracellular Na+1. J Pharmacol Exp Ther 1999;290:1363-1368.

91. Wonnemann M, Singer A, Siebert B, Muller WE. Evaluation of synaptosomal uptake inhibition of most relevant constituents of St. John's wort. Pharmacopsychiatry 2001;34 Suppl 1:S148-S151.

92. Wonnemann M, Singer A, Muller WE. Inhibition of synaptosomal uptake of 3H-l-glutamate and 3H-GABA by hyperforin, a major constituent of St. John's wort: the role of amiloride sensitive sodium conductive pathways. Neuropsychopharmacology 2000;23:188-197.

93. Simmen U, Burkard W, Berger K et al. Extracts and constituents of Hypericum perforatum inhibit the binding of various ligands to recombinant receptors expressed with the Semliki Forest virus system. J Recept Signal Transduct Res 1999;19:59-74.

94. Muller WE, Singer A, Wonnemann M. Hyperforin: antidepressant activity by a novel mechanism of action. Pharmacopsychiatry 2001;34 Suppl 1:S98-S102.

95. Eckert GP, Muller WE. Effects of hyperforin on the fluidity of brain membranes. Pharmacopsychiatry 2001;34 Suppl 1:S22-S25.

96. Gobbi M, Moia M, Pirona L et al. In vitro binding studies with two Hypericum perforatum extracts—hyperforin, hypericin and biapigenin—on 5-HT6, 5-HT7, GABA(A)/benzodiazepine, sigma, NPY-Y1/Y2 receptors and dopamine transporters. Pharmacopsychiatry 2001;34 Suppl 1:S45-S48.

97. Muller WE. Current St John's wort research from mode of action to clinical efficacy. Pharmacol Res 2003;47:101-109.

98. Mennini T, Gobbi M. The antidepressant mechanism of Hypericum perforatum. Life Sci 2004;75:1021-1027.

99. Koch E, Chatterjee SS. Hyperforin stimulates intracellular calcium mobilisation and enhances extracellular acidification in DDT1-MF2 smooth muscle cells. Pharmacopsychiatry 2001;34 Suppl 1:S70-S73.

100. Krishtal O, Lozovaya N, Fisunov A et al. Modulation of ion channels in rat neurons by the constituents of Hypericum perforatum. Pharmacopsychiatry 2001;34 Suppl 1:S74-S82.

101. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991;148:705-713.

102. Hilton SE, Maradit H, Moller HJ. Serotonin syndrome and drug combinations: focus on MAOI and RIMA. Eur Arch Psychiatry Clin Neurosci 1997;247:113-119.

103. Radomski JW, Dursun SM, Reveley MA, Kutcher SP. An exploratory approach to the serotonin syndrome: an update of clinical phenomenology and revised diagnostic criteria. Med Hypotheses 2000;55:218-224.

104. Von Halling Laier MG, Gram LF. [Serotonin syndrome and malignant neuroleptic syndrome: a review based on the material from the National Board of Adverse Drug Reactions]. Ugeskr Laeger 1996;158:6933-6937.

105. Woelk H. Comparison of St John's wort and imipramine for treating depression: randomised controlled trial. BMJ 2000;321:536-539.

106. Schrader E. Equivalence of St John's wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression. Int Clin Psychopharmacol 2000;15:61-68.

107. Cott JM, Rosenthal N, Blumenthal M. St John's wort and major depression. JAMA 2001;286:42; author reply 44-45.

108. Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies of major depression: variable, substantial, and growing. JAMA 2002;287:1840-1847.

109. Barbui C, Cipriani A, Brambilla P, Hotopf M. "Wish bias" in antidepressant drug trials? J Clin Psychopharmacol 2004;24:126-130.

110. Markowitz JS, Donovan JL, DeVane CL et al. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 2003;290:1500-1504.

111. Stockley I. Stockley's Drug Interactions. 6th ed. London: Pharmaceutical Press; 2002.

112. Johne A, Schmider J, Brockmoller J et al. Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John's wort (Hypericum perforatum). J Clin Psychopharmacol 2002;22:46-54.

113. Jakovljevic V, Popovic M, Mimica-Dukic N et al. Pharmacodynamic study of Hypericum perforatum L. Phytomedicine 2000;7:449-453.

114. Irefin S, Sprung J. A possible cause of cardiovascular collapse during anesthesia: long-term use of St. John's wort. J Clin Anesth 2000;12:498-499.

115. Choo EF, Leake B, Wandel C et al. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos 2000;28:655-660.

116. Huang L, Wring SA, Woolley JL et al. Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. Drug Metab Dispos 2001;29:754-760.

117. De Maat MM, Hoetelmans RM, Math RA et al. Drug interaction between St John's wort and nevirapine. AIDS 2001;15:420-421.

118. Stebbing J, Bower M. Comparative pharmacogenomics of antiretroviral and cytotoxic treatments. Lancet Oncol 2006;7:61-68.

119. Hebert MF. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Rev 1997;27:201-214.

120. Kwei GY, Alvaro RF, Chen Q et al. Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in MDR1a P-glycoprotein. Drug Metab Dispos 1999;27:581-587.

121. Wu CY, Benet LZ, Hebert MF et al. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther 1995;58:492-497.

122. Bauer S, Stormer E, Johne A et al. Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients. Br J Clin Pharmacol 2003;55:203-211.

123. Mandelbaum A, Pertzborn F, Martin-Facklam M, Wiesel M. Unexplained decrease of cyclosporin trough levels in a compliant renal transplant patient. Nephrol Dial Transplant 2000;15:1473-1474.

124. Mai I, Kruger H, Budde K et al. Hazardous pharmacokinetic interaction of Saint John's wort (Hypericum perforatum) with the immunosuppressant cyclosporin. Int J Clin Pharmacol Ther 2000;38:500-502.

125. Breidenbach T, Kliem V, Burg M et al. Profound drop of cyclosporin A whole blood trough levels caused by St. John's wort (Hypericum perforatum). Transplantation 2000;69:2229-2230.

126. Barone GW, Gurley BJ, Ketel BL et al. Drug interaction between St. John's wort and cyclosporine. Ann Pharmacother 2000;34:1013-1016.

127. Karliova M, Treichel U, Malago M et al. Interaction of Hypericum perforatum (St. John's wort) with cyclosporin A metabolism in a patient after liver transplantation. J Hepatol 2000;33:853-855.

128. Mueller SC, Uehleke B, Woehling H et al. Effect of St John's wort dose and preparations on the pharmacokinetics of digoxin. Clin Pharmacol Ther 2004;75:546-557.

129. Kullak-Ublick GA, Ismair MG, Stieger B et al. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 2001;120:525-533.

130. Dresser GK, Bailey DG, Leake BF et al. Fruit juices inhibit organic anion transporting polypeptide–mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 2002;71:11-20.

131. Mikkaichi T, Suzuki T, Onogawa T et al. Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci USA 2004;101:3569-3574.

132. Andelic S. [Bigeminy: the result of interaction between digoxin and St. John's wort]. Vojnosanit Pregl 2003;60:361-364.

133. Dresser GK, Bailey DG. The effects of fruit juices on drug disposition: a new model for drug interactions. Eur J Clin Invest 2003;33 Suppl 2:10-16.

134. Peebles KA, Baker RK, Kurz EU et al. Catalytic inhibition of human DNA topoisomerase IIα by hypericin, a naphthodianthrone from St. John's wort (Hypericum perforatum). Biochem Pharmacol 2001;62:1059-1070.

135. Block KI, Gyllenhaal C. Clinical corner. Herb-drug interactions in cancer chemotherapy: theoretical concerns regarding drug metabolizing enzymes. Integr Cancer Ther 2002;1:83-89.

136. Wang Z, Hamman MA, Huang SM et al. Effect of St John's wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther 2002;71:414-420.

137. Frye RF, Fitzgerald SM, Lagattuta TF, Egorin MJ. Effect of St. John's wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther 2004;75:P96.

138. Rochat B. Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism. Clin Pharmacokinet 2005;44:349-366.

139. Mathijssen RH, Loos WJ, Verweij J, Sparreboom A. Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan. Curr Cancer Drug Targets 2002;2:103-123.

140. Mathijssen RH, van Alphen RJ, Verweij J et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001;7:2182-2194.

141. Rivory LP. Metabolism of CPT-11: impact on activity. Ann NY Acad Sci 2000;922:205-215.

142. Perry M. The Chemotherapy Source Book. 3rd ed. Philadelphia: Lippincott, Williams & Wilkins; 2001.

143. Mansky PJ, Straus SE. St. John's wort: more implications for cancer patients. J Natl Cancer Inst 2002;94:1187-1188.

144. Sparreboom A, Cox MC, Acharya MR, Figg WD. Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol 2004;22:2489-2503.

145. Xie HG. Additional discussions regarding the altered metabolism and transport of omeprazole after long-term use of St John's wort. Clin Pharmacol Ther 2005;78:440-441.

146. Donovan JL, DeVane CL, Lewis JG et al. Effects of St John's wort (Hypericum perforatum L.) extract on plasma androgen concentrations in healthy men and women: a pilot study. Phytother Res 2005;19:901-906.

147. Hall SD, Wang Z, Huang SM et al. The interaction between St John's wort and an oral contraceptive. Clin Pharmacol Ther 2003;74:525-535.

148. Pfrunder A, Schiesser M, Gerber S et al. Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial. Br J Clin Pharmacol 2003;56:683-690.

149. Pregnancies prompt herb warning. BBC News; Feb 6, 2002.

150. Yue QY, Bergquist C, Gerden B. Safety of St John's wort (Hypericum perforatum). Lancet 2000;355:576-577.

151. Barditch-Crovo P, Trapnell CB, Ette E et al. The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive. Clin Pharmacol Ther 1999;65:428-438.

152. LeBel M, Masson E, Guilbert E et al. Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone. J Clin Pharmacol 1998;38:1042-1050.

153. Komoroski BJ, Parise RA, Egorin MJ et al. Effect of the St. John's wort constituent hyperforin on docetaxel metabolism by human hepatocyte cultures. Clin Cancer Res 2005;11:6972-6979.

154. Wada A, Sakaeda T, Takara K et al. Effects of St John's wort and hypericin on cytotoxicity of anticancer drugs. Drug Metab Pharmacokinet 2002;17:467-474.

155. Engels FK, Ten Tije AJ, Baker SD et al. Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. Clin Pharmacol Ther 2004;75:448-454.

156. Engels FK, Sparreboom A, Mathot RA, Verweij J. Potential for improvement of docetaxel-based chemotherapy: a pharmacological review. Br J Cancer 2005;93:173-177.

157. Cozza K, Armstrong S, Oesterheld J. Drug Interaction Principles for Medical Practice. 2nd ed. Washington, DC: American Psychiatric Publishing; 2003.

158. Neuvonen PJ, Pohjola-Sintonen S, Tacke U, Vuori E. Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses. Lancet 1993;342:1419.

159. Gordon JB. SSRIs and St. John's wort: possible toxicity? Am Fam Physician 1998;57:950, 953.

160. Nierenberg AA, Burt T, Matthews J, Weiss AP. Mania associated with St. John's wort. Biol Psychiatry 1999;46:1707-1708.

161. Prost N, Tichadou L, Rodor F et al. [St. John's wort–venlafaxine interaction]. Presse Med 2000;29:1285-1286.

162. Spinella M, Eaton LA. Hypomania induced by herbal and pharmaceutical psychotropic medicines following mild traumatic brain injury. Brain Inj 2002;16:359-367.

163. Sugimoto K, Ohmori M, Tsuruoka S et al. Different effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther 2001;70:518-524.

164. Bogman K, Peyer AK, Torok M et al. HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br J Pharmacol 2001;132:1183-1192.

165. Bolley R, Zulke C, Kammerl M et al. Tacrolimus-induced nephrotoxicity unmasked by induction of the CYP3A4 system with St John's wort. Transplantation 2002;73:1009.

166. Hebert MF, Park JM, Chen Y-L et al. Effects of St. John's wort (Hypericum perforatum) on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol 2004;44:89-94.

167. Mai I, Stormer E, Bauer S et al. Impact of St John's wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. Nephrol Dial Transplant 2003;18:819-822.

168. Tannergren C, Engman H, Knutson L et al. St John's wort decreases the bioavailability of R- and S-verapamil through induction of the first-pass metabolism. Clin Pharmacol Ther 2004;75:298-309.

169. Maurer A, Johne A, Bauer S et al. Interaction of St John's Wort extract with phenprocoumon. European Journal Clinical Pharmacology 1999;55:(abstract 22).

170. Keller C, Matzdorff AC, Kemkes-Matthes B. Pharmacology of warfarin and clinical implications. Semin Thromb Hemost 1999;25:13-16.

171. He M, Korzekwa KR, Jones JP et al. Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9. Arch Biochem Biophys 1999;372:16-28.

172. Noldner M, Chatterjee S. Effects of two different extracts of St. John's wort and some of their constituents on cytochrome P450 activities in rat liver microsomes. Pharmacopsychiatry 2001;34 Suppl 1:S108-S110.

173. Wadelius M, Sorlin K, Wallerman O et al. Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. Pharmacogenomics J 2004;4:40-48.

174. Takahashi H, Echizen H. Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin. Pharmacogenomics J 2003;3:202-214.

175. Scordo MG, Pengo V, Spina E et al. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 2002;72:702-710.

176. Kamali F, Khan TI, King BP et al. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol Ther 2004;75:204-212.

177. Takahashi H, Wilkinson GR, Caraco Y et al. Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clin Pharmacol Ther 2003;73:253-263.

178. Jiang X, Williams KM, Liauw WS et al. Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 2004;57:592-599.

179. Wells PS, Holbrook AM, Crowther NR, Hirsh J. Interactions of warfarin with drugs and food. Ann Intern Med 1994;121:676-683.

180. Uehleke B. Hypericum interactions: an update. Sixth International ESCOP Scientific Symposium. Bonn Germany; 2001. http://www.phytotherapy.org/gphy/6IS-ESCOP.htm.

181. Khawaja IS, Marotta RF, Lippmann S. Herbal medicines as a factor in delirium. Psychiatr Serv 1999;50:969-970.

182. Zullino D, Borgeat F. Hypertension induced by St. John's wort: a case report. Pharmacopsychiatry 2003;36:32.

183. Patel S, Robinson R, Burk M. Hypertensive crisis associated with St. John's wort. Am J Med 2002;112:507-508.

184. Hopfner M, Maaser K, Theiss A et al. Hypericin activated by an incoherent light source has photodynamic effects on esophageal cancer cells. Int J Colorectal Dis 2003;18:239-247.

185. Ladner DP, Klein SD, Steiner RA, Walt H. Synergistic toxicity of delta-aminolaevulinic acid–induced protoporphyrin IX used for photodiagnosis and Hypericum extract, a herbal antidepressant. Br J Dermatol 2001;144:916-918.

186. Kelty CJ, Brown NJ, Reed MW, Ackroyd R. The use of 5-aminolaevulinic acid as a photosensitiser in photodynamic therapy and photodiagnosis. Photochem Photobiol Sci 2002;1:158-168.

187. Nebel A, Schneider BJ, Baker RK, Kroll DJ. Potential metabolic interaction between St. John's wort and theophylline [letter]. Ann Pharmacother 1999;33:502.

188. Morimoto T, Kotegawa T, Tsutsumi K et al. Effect of St. John's wort on the pharmacokinetics of theophylline in healthy volunteers. J Clin Pharmacol 2004;44:95-101.